Latest Breaking News On - Peter hillmen - Page 2 : comparemela.com

Measurable Residual Disease-Guided Therapy Promising in CLL

The ibrutinib-venetoclax combination was particularly effective in patients with chronic lymphocytic leukemia with high-risk features such as IGHV unmutated disease or chromosomal abnormalities.

United statesUnited kingdomMikkaela sekeresLee greenbergerUniversity of miami miller school medicineAmerican society of hematologyLeukemia lymphoma societyPeter hillmenLeeds instituteMedical researchUniversity hospitalAmerican societyNew england journalMiami miller schoolMedscape medical newsChronic lymphocytic leukemia lymphoid cll leukaemia

New Gold Standard for Previously Untreated CLL

Personalized, time-limited regimen of venetoclax plus ibrutinib improves survival versus FCR

United statesUnited kingdomMikkael sekeresUk national cancer research instituteAmerican society of hematologyUniversity of miami miller school medicineInternational workshop on chronic lymphocytic leukemiaJames university hospital in leedsPeter hillmenUniversity hospitalAmerican societyMiami miller schoolCancer research instituteInternational workshopChronic lymphocytic leukemiaManaging editor

Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard of Care Regimen for Previously Untreated CLL

This is the first trial to show that a MRD-guided approach with treatment beyond MRD negativity has a significant advantage over chemotherapy, both in terms of PFS and OS.

United kingdomUnited statesAmerican society of hematologyUniversity of leedsInternational workshop on chronic lymphocytic leukemiaPeter hillmenAmerican societyAnnual meetingLeeds teaching hospitalsInternational workshopChronic lymphocytic leukemiaBinet stage

MRD-Guided Ibrutinib Plus Venetoclax Improves Survival in Treatment-Naive CLL

Ibrutinib plus venetoclax, given at a duration determined by minimal residual disease, improved progression-free survival and overall survival vs fludarabine, cyclophosphamide, and rituximab in patients with treatment-naive chronic lymphocytic leukemia.

United kingdomInternational working groupPeter hillmenLeeds teaching hospitalsChronic lymphocytic leukemiaFlair trial2023 ash annual meeting

Unequivocal data emerges from trial of CLL therapy guided by minimal residual disease

Unequivocal data emerges from trial of CLL therapy guided by minimal residual disease
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSan diegoIbrutinib imbruvicaUniversity of leeds school medicinePeter hillmenLeeds schoolLeeds teaching hospitals